web analytics
-0.8 C
Munich
Saturday, November 26, 2022

Provisional Patent Applications, GRPS Agreement Drive Up Premier Biomedical Inc (OTCMKTS:BIEI)

Premier Biomedical Inc (OTCMKTS:BIEI) has been on a wild run in recent weeks attracting legions of shareholders and establishing itself as a volume leader in small caps. Investors are accumulating BIEI since the Company is making progress in its pursuit of a cure for severely ill patients suffering from the Coronavirus pandemic.Recently the Company has filed 2 seperate provisional patent applications; Method for Treating and Curing Covid-19 Infection, by Mitchell S. Felder, M.D., the Chairman of the Board and Scientific Advisory Board Chairman of Premier Biomedical as well as “Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients,” by Mitchell S. Felder, M.D., the Chairman of the Board and Scientific Advisory Board Chairman of Premier Biomedical.

More recently BIEI signed a multi-faceted agreement for ongoing R&D into a potential treatment and cure for Covid-19 as well as development of Premier’s Anti-Addiction Patch™ with Gold River Productions Inc. BIEI management team led by William A. Hartman recently stated: “We believe that our extracorporeal approach could cure severely ill Covid-19 infected patients without causing any undesirable side effects, such as “cytokine storm”, via the removal of certain non-structural proteins which the Covid-19 virus needs for replication.”

Premier Biomedical Inc (OTCMKTS:BIEI)  bills itself as a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania.

To Find out the inside Scoop on BIEI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

BIEI

Back in March, BIEI announced the filing of a provisional patent application, Method for Treating and Curing Covid-19 Infection, by Mitchell S. Felder, M.D., the Chairman of the Board and Scientific Advisory Board Chairman of Premier Biomedical. Through its exclusive global patent license agreement, Premier Biomedical will have exclusive rights to practice the invention. The patent application involves the removal of disease-specific antigens via an extracorporeal process. These antigens are associated with the ability of Covid-19 to replicate. By targeting these disease antigens with a complexing agent and causing them to bind together, the resulting molecular compound can then be removed in a brief clinical process.

This was followed by the filing of a 2nd provisional patent application, “Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients,” by Mitchell S. Felder, M.D., the Chairman of the Board and Scientific Advisory Board Chairman of Premier Biomedical. Through its exclusive global patent license agreement, Premier Biomedical will have exclusive rights to practice the invention.

Last week the Company signed a multi-faceted agreement for ongoing R&D into a potential treatment and cure for Covid-19 as well as development of Premier’s Anti-Addiction Patch™. The Joint Venture on Covid-19 treatment starts with Dr. Mitchell Felder’s patented extracorporeal therapy (US Patent 9,216,386 and US Patent 8,758,287) for the safe removal of targeted antigens from the blood and targeted organs. Dr. Felder explained, “The extracorporeal treatment is based on the process of removing the underlying basis of the disease. In the case of Covid-19, it entails removal of specific compounds which allow the virus to replicate. We believe this technology is superior to known treatments in that it may potentially eliminate mutations of the virus.”

Premier Biomedical recently stated: “Scientists with whom we have consulted believe that our patented process could lead to a cure for Covid-19 without invoking any undesirable side effects, since nothing would be added to the patient’s blood.” According to management:  “Premier has repeatedly proven in the laboratory that we can remove specific selected blood-borne antigens from a similar mixture using our patented technology. This intellectual property is an expansion of our two U.S. granted patents: Sequential Extracorporeal Treatment of Bodily Fluids, US Patent No. 9,216,386, and Utilization of Stents for the treatment of Blood Borne Carcinomas, U.S. Patent No. 8,758,287. Both patents can be downloaded from the Premier Biomedical, Inc. website.

We have a Monster Pick Coming. Subscribe Right Now!

Currently on the move up BIEI management recently announced a multi-faceted agreement to eliminate the Convertible Notes as an obligation of Premier, cancel the previously announced plans for a reverse split, and secure near-term funding for ongoing R&D into a potential cure for Covid-19 as well as Premier’s Anti-Addiction Patch™. BIEI has been on the move since the Company announced the filing of 2 provisional patent applicatios as well as a ongoing R&D agreement with GRPS to develop a potential treatment and cure for Covid-19. BIEI management team led by William A. Hartman recently stated: “We believe that our extracorporeal approach could cure severely ill Covid-19 infected patients without causing any undesirable side effects, such as “cytokine storm”, via the removal of certain non-structural proteins which the Covid-19 virus needs for replication.”  We will be updating on BIEI when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with BIEI.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in BIEI either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.